Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Paul S, Planque S, Nishiyama Y.

J Clin Immunol. 2010 May;30 Suppl 1:S43-9. doi: 10.1007/s10875-010-9414-5. Review.


Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S.

Autoimmun Rev. 2008 May;7(5):391-7. doi: 10.1016/j.autrev.2008.03.004. Epub 2008 Apr 9. Review.


Autoantibody-catalyzed hydrolysis of amyloid beta peptide.

Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S.

J Biol Chem. 2008 Feb 22;283(8):4714-22. Epub 2007 Dec 17.


Beneficial catalytic immunity to abeta peptide.

Paul S, Planque S, Nishiyama Y.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):179-87. doi: 10.1089/rej.2009.0958. Review.


Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M.

J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.


Specific amyloid β clearance by a catalytic antibody construct.

Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hara M, Kolodziej S, Mitsuda Y, Gonzalez V, Sait HB, Fukuchi K, Massey RJ, Friedland RP, O'Nuallain B, Sigurdsson EM, Paul S.

J Biol Chem. 2015 Apr 17;290(16):10229-41. doi: 10.1074/jbc.M115.641738. Epub 2015 Feb 27.


Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.

Wang T, Xie XX, Ji M, Wang SW, Zha J, Zhou WW, Yu XL, Wei C, Ma S, Xi ZY, Pang GL, Liu RT.

Neuropharmacology. 2016 Jun;105:561-576. doi: 10.1016/j.neuropharm.2016.02.015. Epub 2016 Feb 18.


Natural human antibodies to amyloid beta peptide.

Szabo P, Relkin N, Weksler ME.

Autoimmun Rev. 2008 Jun;7(6):415-20. doi: 10.1016/j.autrev.2008.03.007. Epub 2008 Apr 10. Review.


Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.

Klaver AC, Coffey MP, Smith LM, Loeffler DA.

Immunol Lett. 2013 Jul-Aug;154(1-2):7-11. doi: 10.1016/j.imlet.2013.07.008. Epub 2013 Aug 6.


Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo.

Cattepoel S, Gaida A, Kropf A, Nolte MW, Bolli R, Miescher SM.

PLoS One. 2016 Aug 25;11(8):e0161826. doi: 10.1371/journal.pone.0161826. eCollection 2016.


Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration.

Loeffler DA, Klaver AC, Coffey MP.

Autoimmunity. 2015 Jun;48(4):196-200. doi: 10.3109/08916934.2014.983265. Epub 2014 Nov 13.


Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.

Kou J, Yang J, Lim JE, Pattanayak A, Song M, Planque S, Paul S, Fukuchi K.

Mol Neurobiol. 2015 Feb;51(1):43-56. doi: 10.1007/s12035-014-8691-z. Epub 2014 Apr 15.


Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG?

Warrington AE, Van Keulen V, Pease LR, Rodriguez M.

Adv Exp Med Biol. 2012;750:44-55. doi: 10.1007/978-1-4614-3461-0_4.


Naturally occurring autoantibodies against β-Amyloid.

Bach JP, Dodel R.

Adv Exp Med Biol. 2012;750:91-9. doi: 10.1007/978-1-4614-3461-0_7. Review.


Intravenous immunoglobulins for Alzheimer's disease.

Puli L, Tanila H, Relkin N.

Curr Alzheimer Res. 2014;11(7):626-36. Review.


Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies.

O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, Wall JS, Weiss DT, Solomon A.

Biochemistry. 2008 Nov 25;47(47):12254-6. doi: 10.1021/bi801767k.


Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies.

Lindhagen-Persson M, Brännström K, Vestling M, Steinitz M, Olofsson A.

PLoS One. 2010 Nov 10;5(11):e13928. doi: 10.1371/journal.pone.0013928.


Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Qu BX, Gong Y, Moore C, Fu M, German DC, Chang LY, Rosenberg R, Diaz-Arrastia R.

J Neuroimmunol. 2014 Sep 15;274(1-2):168-73. doi: 10.1016/j.jneuroim.2014.06.017. Epub 2014 Jun 27.


Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M.

J Neurosci. 2011 Apr 13;31(15):5847-54. doi: 10.1523/JNEUROSCI.4401-10.2011.


Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Söllvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S, Lannfelt L, Sehlin D.

J Alzheimers Dis. 2015;48(1):63-72. doi: 10.3233/JAD-150236.

Supplemental Content

Support Center